HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Discovery of dual function acridones as a new antimalarial chemotype.

Abstract
Preventing and delaying the emergence of drug resistance is an essential goal of antimalarial drug development. Monotherapy and highly mutable drug targets have each facilitated resistance, and both are undesirable in effective long-term strategies against multi-drug-resistant malaria. Haem remains an immutable and vulnerable target, because it is not parasite-encoded and its detoxification during haemoglobin degradation, critical to parasite survival, can be subverted by drug-haem interaction as in the case of quinolines and many other drugs. Here we describe a new antimalarial chemotype that combines the haem-targeting character of acridones, together with a chemosensitizing component that counteracts resistance to quinoline antimalarial drugs. Beyond the essential intrinsic characteristics common to deserving candidate antimalarials (high potency in vitro against pan-sensitive and multi-drug-resistant Plasmodium falciparum, efficacy and safety in vivo after oral administration, inexpensive synthesis and favourable physicochemical properties), our initial lead, T3.5 (3-chloro-6-(2-diethylamino-ethoxy)-10-(2-diethylamino-ethyl)-acridone), demonstrates unique synergistic properties. In addition to 'verapamil-like' chemosensitization to chloroquine and amodiaquine against quinoline-resistant parasites, T3.5 also results in an apparently mechanistically distinct synergism with quinine and with piperaquine. This synergy, evident in both quinoline-sensitive and quinoline-resistant parasites, has been demonstrated both in vitro and in vivo. In summary, this innovative acridone design merges intrinsic potency and resistance-counteracting functions in one molecule, and represents a new strategy to expand, enhance and sustain effective antimalarial drug combinations.
AuthorsJane X Kelly, Martin J Smilkstein, Reto Brun, Sergio Wittlin, Roland A Cooper, Kristin D Lane, Aaron Janowsky, Robert A Johnson, Rozalia A Dodean, Rolf Winter, David J Hinrichs, Michael K Riscoe
JournalNature (Nature) Vol. 459 Issue 7244 Pg. 270-3 (May 14 2009) ISSN: 1476-4687 [Electronic] England
PMID19357645 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Acridones
  • Antimalarials
  • Membrane Transport Proteins
  • PfCRT protein, Plasmodium falciparum
  • Protozoan Proteins
  • Quinolines
  • chloro-6-(2-diethylamino-ethoxy)-10-(2-diethylamino-ethyl)acridone
  • Heme
  • piperaquine
  • Quinine
  • Verapamil
  • quinoline
Topics
  • Acridones (analysis, metabolism, pharmacology)
  • Animals
  • Antimalarials (analysis, metabolism, pharmacology)
  • Drug Discovery
  • Drug Resistance (drug effects)
  • Drug Synergism
  • Heme (antagonists & inhibitors, metabolism)
  • Membrane Transport Proteins (genetics, metabolism)
  • Mutation (genetics)
  • Plasmodium falciparum (drug effects, genetics, growth & development, metabolism)
  • Plasmodium yoelii (drug effects)
  • Protozoan Proteins (genetics, metabolism)
  • Quinine (pharmacology)
  • Quinolines (pharmacology)
  • Trophozoites (metabolism)
  • Verapamil (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: